These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
483 related articles for article (PubMed ID: 14500738)
1. Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine. Malherbe P; Kratochwil N; Zenner MT; Piussi J; Diener C; Kratzeisen C; Fischer C; Porter RH Mol Pharmacol; 2003 Oct; 64(4):823-32. PubMed ID: 14500738 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the binding pockets of two chemically unrelated allosteric antagonists of the mGlu5 receptor and identification of crucial residues involved in the inverse agonism of MPEP. Malherbe P; Kratochwil N; Mühlemann A; Zenner MT; Fischer C; Stahl M; Gerber PR; Jaeschke G; Porter RH J Neurochem; 2006 Jul; 98(2):601-15. PubMed ID: 16805850 [TBL] [Abstract][Full Text] [Related]
3. Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor. Malherbe P; Kratochwil N; Knoflach F; Zenner MT; Kew JN; Kratzeisen C; Maerki HP; Adam G; Mutel V J Biol Chem; 2003 Mar; 278(10):8340-7. PubMed ID: 12509432 [TBL] [Abstract][Full Text] [Related]
4. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Gasparini F; Lingenhöhl K; Stoehr N; Flor PJ; Heinrich M; Vranesic I; Biollaz M; Allgeier H; Heckendorn R; Urwyler S; Varney MA; Johnson EC; Hess SD; Rao SP; Sacaan AI; Santori EM; Veliçelebi G; Kuhn R Neuropharmacology; 1999 Oct; 38(10):1493-503. PubMed ID: 10530811 [TBL] [Abstract][Full Text] [Related]
5. The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. Pagano A; Ruegg D; Litschig S; Stoehr N; Stierlin C; Heinrich M; Floersheim P; Prezèau L; Carroll F; Pin JP; Cambria A; Vranesic I; Flor PJ; Gasparini F; Kuhn R J Biol Chem; 2000 Oct; 275(43):33750-8. PubMed ID: 10934211 [TBL] [Abstract][Full Text] [Related]
6. A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Rodriguez AL; Nong Y; Sekaran NK; Alagille D; Tamagnan GD; Conn PJ Mol Pharmacol; 2005 Dec; 68(6):1793-802. PubMed ID: 16155210 [TBL] [Abstract][Full Text] [Related]
7. [3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. Anderson JJ; Rao SP; Rowe B; Giracello DR; Holtz G; Chapman DF; Tehrani L; Bradbury MJ; Cosford ND; Varney MA J Pharmacol Exp Ther; 2002 Dec; 303(3):1044-51. PubMed ID: 12438526 [TBL] [Abstract][Full Text] [Related]
8. Selective blockade of mGlu5 metabotropic glutamate receptors protects rat hepatocytes against hypoxic damage. Storto M; de Grazia U; Knöpfel T; Canonico PL; Copani A; Richelmi P; Nicoletti F; Vairetti M Hepatology; 2000 Mar; 31(3):649-55. PubMed ID: 10706555 [TBL] [Abstract][Full Text] [Related]
9. N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. Chen Y; Goudet C; Pin JP; Conn PJ Mol Pharmacol; 2008 Mar; 73(3):909-18. PubMed ID: 18056795 [TBL] [Abstract][Full Text] [Related]
10. Identification of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Acting at Site Distinct from 2-Methyl-6-(phenylethynyl)-pyridine Binding. Butkiewicz M; Rodriguez AL; Rainey SE; Wieting J; Luscombe VB; Stauffer SR; Lindsley CW; Conn PJ; Meiler J ACS Chem Neurosci; 2019 Aug; 10(8):3427-3436. PubMed ID: 31132237 [TBL] [Abstract][Full Text] [Related]
11. Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors. Lea PM; Movsesyan VA; Faden AI Br J Pharmacol; 2005 Jun; 145(4):527-34. PubMed ID: 15821750 [TBL] [Abstract][Full Text] [Related]
12. Orthosteric and allosteric drug binding sites in the Caenorhabditis elegans mgl-2 metabotropic glutamate receptor. Tharmalingam S; Burns AR; Roy PJ; Hampson DR Neuropharmacology; 2012 Sep; 63(4):667-74. PubMed ID: 22652059 [TBL] [Abstract][Full Text] [Related]
19. Determination of key amino acids implicated in the actions of allosteric modulation by 3,3'-difluorobenzaldazine on rat mGlu5 receptors. Mühlemann A; Ward NA; Kratochwil N; Diener C; Fischer C; Stucki A; Jaeschke G; Malherbe P; Porter RH Eur J Pharmacol; 2006 Jan; 529(1-3):95-104. PubMed ID: 16352303 [TBL] [Abstract][Full Text] [Related]
20. Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Battaglia G; Busceti CL; Molinaro G; Biagioni F; Storto M; Fornai F; Nicoletti F; Bruno V J Neurosci; 2004 Jan; 24(4):828-35. PubMed ID: 14749427 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]